Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Coherus announces proposed public offering of common stock
-
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
-
Coherus to Participate in Upcoming Investor Conferences
-
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
-
TD Cowen Reiterates Buy Rating on Coherus Biosciences (CHRS)
-
TD Cowen Reiterates Buy Rating on Coherus Biosciences (CHRS)
-
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
-
Coherus BioSciences (CHRS) Increases ATM Offering Program by $28.75M
-
Coherus BioSciences to Present at Upcoming Investor Conferences in March
-
Coherus Management to Present at Upcoming Investor Conferences
-
Coherus Management to Present at Upcoming Investor Conferences
-
Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
-
Pre-Open Stock Movers 04/08: (CHRS) (NBEV) (SNAP) Higher; (ROKU) (GE) (BA) Lower (more...)
-
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
-
Coherus Biosciences (CHRS) PT Lowered to $35 at Cowen
-
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
-
IPR Decision Disappointing for Coherus Biosciences (CHRS) But Focus Remains on Neulasta - Cowen
-
Coherus Biosciences (CHRS) Neulasta Biosimilar Delay 'Appears Resolvable' - Cowen
-
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
-
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
-
Coherus BioSciences (CHRS) Prices 5.15M Shares at $24.25
-
Coherus Prices Public Offering of Common Stock
-
Coherus BioSciences (CHRS) Commences $125M Offering of Common Stock
-
Coherus Announces Proposed Public Offering of Common Stock
-
Coherus BioSciences to Present at Cowen and Company Healthcare Conference on March 8
-
Coherus BioSciences (CHRS) Prices Larger 4.14M Common Offering at $29/Share
-
Coherus Prices Upsized Public Offering of $120.0 Million of Common Stock
-
Coherus Prices Upsized Public Offering of $120.0 Million of Common Stock
-
Coherus BioSciences (CHRS) to Offer $100M in Common Stock
-
Coherus Announces Proposed Public Offering of Common Stock
-
Coherus Announces Proposed Public Offering of Common Stock
-
Coherus BioSciences to Present at Cowen and Company Health Care Conference on March 2
-
Cowen Starts Coherus Biosciences (CHRS) at Outperform
-
Coherus BioSciences Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares
-
Coherus BioSciences (CHRS) IPO Opens Lower
-
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock

